Yann Teyssier

Centre Hospitalier Universitaire de Grenoble

Papers

1

Total Citations

32

H-Index

1

About

Yann Teyssier is a pioneering urologic surgeon and researcher whose work centers on advancing robotic-assisted kidney surgery, particularly in the realm of nephron-sparing techniques. His major contributions lie in rigorously evaluating surgical approaches to partial nephrectomy, with a focus on balancing oncologic control against renal function preservation. Teyssier led the landmark EMERALD randomized controlled trial, which demonstrated that superselective ischemia during robotic partial nephrectomy does not yield superior long-term renal outcomes compared to standard renal artery clamping, despite its added technical complexity and risk. This high-impact study, with 32 citations, has directly influenced clinical guidelines by challenging the assumed benefits of superselective ischemia. His research provides critical evidence for surgeons weighing the trade-offs between ischemic techniques, emphasizing that patient safety and functional outcomes must guide practice. Through methodologically robust trials, Teyssier has established himself as a key voice in urologic oncology, helping to refine the standard of care for kidney cancer surgery. His work is essential reading for trainees and specialists alike, offering clear, data-driven insights into one of the most debated aspects of robotic partial nephrectomy.

Research Focus

Key Achievements

1
H-Index
1
Papers
32
Total Citations
32
Avg Citations/Paper
🏆 Most Cited Paper
Superselective Ischemia in Robotic Partial Nephrectomy Does Not Provide Better Long-term Renal Function than Renal Artery Clamping in a Randomized Controlled Trial (EMERALD): Should We Take the Risk?
32 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Centre Hospitalier Universitaire de Grenoble

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago